Eloralintide — also known as MEDI0382 or cotadutide — is a 31-amino acid dual GLP-1R/GCGR co-agonist developed by AstraZeneca/MedImmune. It simultaneously activates two receptors: the GLP-1 receptor (incretin pathway — appetite suppression, insulin secretion, gastric emptying) and the glucagon receptor (GCGR — hepatic fatty acid β-oxidation via CPT1A upregulation, brown adipose thermogenesis via UCP1, energy expenditure increase).
The GCGR component is the defining feature that separates eloralintide from semaglutide and tirzepatide. While both of those reduce liver fat secondarily through weight loss, eloralintide’s GCGR activation drives CPT1A-mediated fatty acid β-oxidation directly in the liver — independent of body weight changes. This is why Phase 2 NASH data shows ~40–50% liver fat reduction with only ~10–11% total body weight loss: the GCGR pathway is working on hepatic fat in parallel.
Why GCGR matters for NASH research: GCGR activation → cAMP/PKA → CPT1A upregulation — the rate-limiting enzyme in mitochondrial fatty acid β-oxidation. This drives direct hepatic fat reduction independent of body weight loss, explaining why eloralintide produces ~40–50% liver fat reduction with only ~10–11% weight loss. No other approved GLP-1 class compound (semaglutide, tirzepatide) has this direct hepatic mechanism.
Energy expenditure ↑ confirmed · hepatic glucose production ↓ · GCGR mechanism verified
GLP-1 Class Positioning
Compound
Receptors
Best Weight Loss
Liver Fat / NASH
GCGR
Semaglutide
GLP-1R
−14.9% (STEP 1)
Secondary via weight loss
✗
Tirzepatide
GLP-1R+GIPR
−20.9% (SURMOUNT-1)
SYNERGY-NASH 62.4%
✗
Eloralintide ★
GLP-1R+GCGR
~10–11% (Ph 2b, 26w)
~40–50% liver fat ↓ (direct GCGR/CPT1A)
✓ CPT1A/UCP1
Survodutide
GLP-1R+GCGR
~15% (Phase 2)
Phase 2 NASH positive
✓
Retatrutide
GLP-1R+GIPR+GCGR
−24.2% (Phase 2)
GCGR+GIPR combination
✓
Compound Specifications
INN / Name
Eloralintide
Research Names
MEDI0382, Cotadutide
Drug Class
Dual GLP-1R/GCGR Co-Agonist
Structure
31 amino acids · ~3,968 Da · synthetic peptide
CAS Number
1884736-23-5
Developer
AstraZeneca / MedImmune
Half-Life
~12 hours (once-daily in Phase 2 trials)
Route (research)
Subcutaneous injection
QSC Purity
≥99% HPLC · MS confirmed · Janoshik COA
Storage
−20°C lyophilised · 2–8°C reconstituted (use within 28 days)
US Shipping
US Domestic Warehouse · 2–4 business days
Frequently Asked Questions
What is eloralintide?
Eloralintide (MEDI0382, cotadutide) is a 31-amino acid dual GLP-1R/GCGR co-agonist developed by AstraZeneca/MedImmune. It simultaneously activates the GLP-1 receptor (appetite suppression, insulin secretion, gastric emptying) and the glucagon receptor (GCGR — hepatic CPT1A upregulation driving direct liver fat oxidation, UCP1-mediated thermogenesis, increased energy expenditure). Phase 2 data: ~10–11% weight loss at 26 weeks; ~40–50% liver fat reduction (MRI-PDFF) in NASH-specific trials.
How does eloralintide differ from semaglutide and tirzepatide?
Eloralintide targets GLP-1R + GCGR (glucagon receptor). Semaglutide targets GLP-1R only. Tirzepatide targets GLP-1R + GIPR. The GCGR component is the defining difference: GCGR agonism drives hepatic CPT1A upregulation and direct fatty acid β-oxidation — reducing liver fat independently of body weight changes. Semaglutide and tirzepatide reduce liver fat secondarily via weight loss. Eloralintide produces ~40–50% liver fat reduction with only ~10–11% weight loss because GCGR is working directly on hepatic fat metabolism.
What clinical data exists for eloralintide?
Phase 2b obesity/T2D (26 weeks): ~10–11% weight reduction vs ~3% placebo. Phase 2 NASH trial (26 weeks): ~40–50% liver fat reduction by MRI-PDFF, significant ALT reduction, NASH histology improvements. Mechanistic Phase 2 (49 days): confirmed increased energy expenditure and reduced hepatic glucose production. Published in The Lancet Diabetes & Endocrinology. Developer: AstraZeneca/MedImmune (MEDI0382).
Is eloralintide the same as MEDI0382 or cotadutide?
Yes — eloralintide, MEDI0382, and cotadutide are the same compound. MEDI0382 was the clinical development code used by AstraZeneca/MedImmune. Cotadutide is an alternative INN used in some publications. Eloralintide is the currently recognised INN. All three refer to the same 31-AA dual GLP-1R/GCGR co-agonist, CAS 1884736-23-5.
Where can I buy research-grade eloralintide?
QSC (qsc-usa.com) is among the first suppliers globally to stock research-grade eloralintide — ≥99% HPLC purity, MS confirmed, Janoshik independent COA (verify.janoshik.com). US Domestic Warehouse: 2–4 business day delivery to all 50 states. International shipping available. Sold strictly for in vitro laboratory research only.
Buy Research-Grade Eloralintide at QSC
≥99% HPLC · MS Confirmed · Janoshik COA · US Domestic 2–4 Days · First mover in stock · Research Use Only
Research Use Only: Eloralintide is sold by QSC strictly for in vitro laboratory research purposes only. Not for human or veterinary use. Not FDA approved for clinical use.
